Zobrazeno 1 - 10
of 19
pro vyhledávání: '"William Buhles"'
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics
Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi‐center, double‐blind, placebo‐controlled, randomized clinical stud
Publikováno v:
Journal of veterinary pharmacology and therapeutics. 41(5)
Single and multiple dose pharmacokinetics (PK) of mirtazapine transdermal ointment applied to the inner ear pinna of cats were assessed. Study 1 was a randomized, cross-over single dose study (n = 8). Cats were treated once with 0.5 mg/kg of mirtazap
Autor:
Philip H. Kass, William Buhles
Publikováno v:
Journal of the American Animal Hospital Association. 48:285-298
Results from investigations conducted in clinical settings contribute greatly to determining how veterinarians practice medicine. It is important for the practitioner to understand how clinical information is collected, analyzed, and communicated in
Autor:
William Buhles
Publikováno v:
New England Journal of Medicine. 365:862-865
Autor:
Robert Andruczk, Jacob Lalezari, Stephen A. Spector, Mary Jean Stempien, Paula D. Sparti, Tobias Samo, George McKinley, Stephen E. Follansbee, William Buhles, Gail Simpson, Diane V. Havlir, Rodney Wong
Publikováno v:
New England Journal of Medicine. 334:1491-1497
Background In the advanced stages of the acquired immunodeficiency syndrome (AIDS), cytomegalovirus (CMV) disease, particularly vision-damaging retinitis due to CMV, is common. We evaluated prophylactic treatment with orally administered ganciclovir
Autor:
W. Lawrence Drew, David Ives, Jacob P. Lalezari, Clyde Crumpacker, Stephen E. Follansbee, Stephen A. Spector, Constance A. Benson, Dorothy N. Friedberg, Larry Hubbard, Mary Jean Stempien, Anna Shadman, William Buhles
Publikováno v:
New England Journal of Medicine. 333:615-620
Background Cytomegalovirus retinitis, a sight-threatening infection associated with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would be an important advance. Methods W
Autor:
Kathryn Squires, Barbara Mastre, W. Lawrence Drew, James D. Connor, Donald Jung, David F. Busch, Stephen E. Follansbee, Anna Shadman, Jacob Lalezari, Stephen A. Spector, William Buhles, Mark A. Jacobson
Publikováno v:
Journal of Infectious Diseases. 171:1431-1437
A phase I/II study evaluated the pharmacokinetics, tolerability, and antiviral activity of oral ganciclovir in persons infected with human immunodeficiency virus (HIV). Oral bioavailability ranged from 2.6% to 7.3%. The mean maximum serum concentrati
Autor:
Lois Kellerman, Thomas A. Weingeist, Tobias Sarno, Richard B. Pollard, Michael Crager, Henry J. Kaplan, Constance A. Benson, William R. Freeman, Douglas T. Dieterich, Bernadette De Armond, Paul R. Montague, David F. Busch, Stephen A. Spector, Judith Feinberg, William Buhles
Publikováno v:
Journal of Infectious Diseases. 168:557-563
This prospective, randomized, multicenter, controlled trial was designed to evaluate the efficacy and safety of intravenous ganciclovir for the treatment of peripheral cytomegalovirus (CMV) retinitis in patients with AIDS. Patients were randomly assi
Autor:
David F. Busch, Douglas T. Dieterich, William Buhles, Clyde S. Crumpacker, D P Kotler, C Du Mond, B. Dearmand
Publikováno v:
Journal of Infectious Diseases. 167:278-282
The efficacy and safety of ganciclovir therapy for cytomegalovirus (CMV) colitis in patients with AIDS was examined in a double-blind, placebo-controlled study. Sixty-two patients at four university medical centers were enrolled. All had biopsy-prove
Autor:
John B. O'Connell, Silvia Resta, Ranae M. Ratkovec, William Buhles, Diane Dunn, Charles DuMond, Susan Keay, Wayne E. Richenbacher, Edward B. Stinson, Michael R. Bristow, Roger C. Millar, Vaughn A. Starnes, Bernadette DeAmond, Thomas C. Merigan, P. Gamberg, Dale G. Renlund, Tricia Cheney, Veronica Sullivan
Publikováno v:
New England Journal of Medicine. 326:1182-1186
Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a cont